Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430001
Status:
UNKNOWN
Last Update Posted:
2008-05-09
First Post:
2007-01-30
Brief Title:
Vinorelbine Plus Trastuzumab vs Docetaxel Plus Trastuzumab as 1 Line Treatment for HER2 Positive Metastatic Breast Cancer
Sponsor:
Danish Breast Cancer Cooperative Group
Organization:
Danish Breast Cancer Cooperative Group
Organization Data
Organization:
Danish Breast Cancer Cooperative Group
Class:
OTHER
Study ID:
HERNATA
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Danish Breast Cancer Cooperative Group
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Sanofi | INDUSTRY |
| Hoffmann-La Roche | INDUSTRY |